InsiderTrades

Form 4 for CADL Candel Therapeutics, Inc.

Accepted 2025-03-20 00:00:00 ET · period of report 2025-03-18 · accession 0000950170-25-042726 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DT 2025-03-20 2025-03-18 CADL Barone Francesca CSO M - OptEx $1.55 +18.0K 128.7K +16% +$27.9K
DT 2025-03-20 2025-03-18 CADL Barone Francesca CSO S - Sale+OE $8.76 -32.1K 96.5K -25% -$281.6K
DT 2025-03-20 2025-03-18 CADL Barone Francesca CSO M - OptEx $0.00 -18.0K 30.8K -37% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-03-18 M A 18,000 $1.55 128,673 D — —
2 Common Common Stock 2025-03-18 S D 32,146 $8.76 96,527 D — — (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.345 to $9.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 herein.
3 Derivative Stock Option (Right to Buy) 2025-03-18 M D 18,000 $0.00 30,822 D $1.55 · — to 2030-12-30 18,000 Common Stock (F3) 25% of the shares underlying this option vested and became exercisable on December 30, 2021, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.